


# Drug Discovery from Natural Products



✓ Mehdi Benidir  
✓ @BenidirM





# Evolution, a Grand Diversity-Generating Machine




*Diversity-generating machine*






*« A primeval tropical jungle, full of the most remarkable things, an amazing thicket, without escape or end, into which one would not dare to enter »*


*Friedrich Wöhler, 1835*









● *TRABECTEDIN*



● *PACLITAXEL*



● *RAPAMYCIN*



● *VANCOMYCIN*



# Natural products

A chemical substance produced by a living organism. This term is often used in reference to small chemical substances found in nature that have distinct pharmacological effects, such as the antibiotic penicillin.



# Natural products

- ✓ « *biological validation* » concept
- ✓ Natural selection



- ✓ Privileged scaffolds
- ✓ Biochemical specificity
- ✓ Structural complexity
- ✓ Highly diversified
- ✓ Efficient chemical space coverage




✓ Discovered 200 years ago by a German pharmacist named Friedrich Sertürner.

# Natural products as exceptions

« *LIPINSKI'S RULE OF FIVE* » [1997]

*THE GUIDELINE FOR THE LIKELIHOOD OF A COMPOUND HAVING ORAL BIOAVAILABILITY (AT LEAST 3 OF THESE CHARACTERISTICS):*

- *MOLECULAR WEIGHT < 500*
- *< 5 H-BOND DONORS*
- *< 10 H-BOND ACCEPTORS*
- *LOG P < 5*





# Sourcing



Plants

Natural  
products

Animals :  
Arthropods,  
marine  
organisms

Micro-  
organisms

# Sourcing

- ✓ Plants have a rich history of use by humans as therapeutics



Ebers papyrus  
(1600 before J.C.)


- ✓ ... 80% of the world population depend either totally or partially on traditional or alternative medicine [WHO]



# Sourcing

## Plants

- ✓ 260 000 plants
  - ✓ Easily accessible (≠ insects and marine organisms)
  - ✓ Traditional uses
  - ✓ 60000 studied plants
- ⇒ 135 drugs




# SOLVING THE CHALLENGE OF TAXOL SUPPLY




**PACIFIC YEW**  
(*TAXUS BREVIFOLIA*)



**EUROPEAN YEW**  
(*TAXUS BACCATA*)



**10-DESACETYLBACCATINE III**  
(**10-DAB**) : PRECURSOR  
~ 0.2 %



**PACLITAXEL**


~ 0.02 %  
[3 TREES (100 YEARS) = 1 G OF  
PACLITAXEL]




# SOLVING THE CHALLENGE OF TAXOL SUPPLY



**PACIFIC YEW**  
(*TAXUS BREVIFOLIA*)



**ACETYLBACCATINE III  
(DAB) : PRECURSOR**  
~ 0.2 %



**PACLITAXEL**

~ 0.02 %  
[3 TREES (100 YEARS) = 1 G OF  
PACLITAXEL]



*INDUSTRIAL PRODUCTION OF TAXOL:*

- *SEMISYNTHESIS FROM 10-DAB*
- *PRODUCED BY PLANT-CELL FERMENTATION*




# ARTEMISININ SUPPLY

- ✓ ACT « artemisinin combination therapy » WHO
- ✓ Estimated needs: 150 tons/year => 400 millions of ACTs (<1\$/day/adult and 0,5\$/day/child)
- ✓ Total synthesis: not profitable
- ✓ Semisynthesis from artemisinic acid



✓ artemisinic acid




R = =O	Artemisinin
R = OMe	Artemether
R = OEt	Arteether
R = OCO(CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> H	Artesunate
R = OH	Dihydroartemisinin




✓ *Artemisia annua*

# Production of plant-derived artemisinin compared to semisynthetic artemisinin.

## Plant-derived Artemisinin



Weeks




## Semisynthetic Artemisinin

Patrick J. Westfall et al. PNAS 2012;109:655-656



# SHIFTING TOWARDS SYNTHETIC BIOLOGY

- ✓ Gene discovery from opium poppy *Papaver somniferum*
- ✓ Gene cloning into *Saccharomyces cerevisiae*



Stanford  
University

# BOOM OF SYNTHETIC BIOLOGY

Toggle switch  
in bacteria




2000

First plant  
genome  
sequence  
*Arabidopsis*



2005

Hydroxy-  
cortisone  
in yeast




Artemisinic acid  
in yeast



2010

Polyphenols  
in yeast




Taxol precursors  
In bacteria




2015


Lignans  
In tobacco




Artemisinin  
in tobacco




Artemisinin  
in yeast





Vinca-  
Alkaloid  
precursors  
In yeast



Noscapine  
in yeast



Ginsenosides  
in yeast




Cannabinoids  
in yeast



2020

New-to-nature  
opioids  
in yeast



# Sourcing

Animals:  
Arthropods,  
marine  
organisms



## Arthropods


- ✓ 1 million described species
- ✓ Insects, spiders
- ✓ Vastly unexplored chemical space

## Marine organisms

- ✓ 500 000 described species
- ✓ A unique chemistry  
(pressure, salinity, temperature,  
halogenation)



*ECTEINASCIDIA TURBINATA*





# Drugs from the sea


- **1967: Symposium Rhode Island (USA)**  
**« Drugs from the Sea »**
- **1970: SCUBA diving advances**
- **50 years later... 40 000 marine compounds discovered and 6 drugs on the market**



**85 % of the known species**

**15 % of the known species  
(80 % of the zoological orders)**


# BIODIVERSITY AND MARINE ECOLOGY






# ECTEINASCIDINE (TRABECTEDINE DCI)

- **STRUCTURE: POLYCYCLIC ALKALOID.**
- **ANTITUMORAL**
- **SUPPLY: ISOLATED FROM *ECTEINASCIDIA TURBINATA*, TUNICATE (FLORIDA KEYS, BAHAMAS, MEDITERRANEAN SEA).**



# ECTEINASCIDINE : INDUSTRIAL PRODUCTION




PharmaMar



# HALICHONDRIINES

- **SOURCE: MARINE SPONGE (*Halichondria okadai*)**
- **ACTIVE COMPOUND: HALICHONDRIINE B**
- **SUPPLY CHALLENGE ? (10 G FOR CLINICAL TRIALS)**




**HALICHONDRIINE B**

*Halichondria okadai*





# HALICHONDRIINES



**AQUACULTURE: LISSODENDORYX SP.**  
**1 TON = 310 MG**


# HALICHONDRIINES

## « THE ART OF TOTAL SYNTHESIS »



# HALICHONDRIINES

« THE ART OF TOTAL SYNTHESIS »






# HALICHONDRIINES: DISCOVERY OF ERIBULINE


**DISCOVERY OF A SIMPLIFIED ANALOGUE: ERIBULINE**

**TARGET: TUBULINE**

**USES: BREAST CANCER (2<sup>ND</sup> INTENTION), HALAVEN<sup>®</sup> (2011)**



- Simplified analogue... but
- 19 chiral centers
- 62 synthesis steps



**ERIBULINE**


# Sourcing

## Micro-organisms




Terrestrial and marine microorganisms (actinomycetes), fungi and bacteria (myxobacteria)

- ✓ A prolific source of antibiotics
- ✓ Highly complex molecular architecture
- ✓ Cultivable (scale-up)



# Bioprospection

## Microbiome complexity and multi-omics analysis timeline



**NATURE PROTOCOLS** | VOL.11 NO.11 | 2016 |



Temperature, moisture, pH, iron concentration...

NP

Soil micro-organisms


**Fungi**  
( $10^4$ - $10^6$ /g)

**Actinomycetes**  
( $10^6$ - $10^8$ /g)

SN

SN

**Bacteria**  
( $10^8$ - $10^9$ /g)





Temperature, moisture, pH, iron concentration...




**Fungi**  
( $10^4$ - $10^6$ /g)



Morphological diversity typical of microorganisms cultured from soil on a broad spectrum medium, tryptic soy agar.

**Bacteria**  
( $10^8$ - $10^9$ /g)



**Actinomycetes**  
( $10^6$ - $10^8$ /g)


N



# Actinomycetes



## The 2015 Nobel Prize in Physiology or Medicine



**William C. Campbell**

Born 1930, Ireland  
Drew University,  
Madison, New Jersey,  
USA



**Satoshi Ōmura**

Born 1935, Japan  
Kitasato University,  
Tokyo, Japan



**Youyou Tu**

Born 1930, China  
China Academy of  
Traditional Chinese  
Medicine, Beijing, China



# Actinomycetes

## ● AVERMECTINS, A GIFT FROM THE SOIL



**STREPTOMYCES AVERMITILIS (RENAMED AS AVERMICTICINIUS) [1974]**

**ORIGIN: JAPANESE SOIL (KAWANA)**

**A MIXTURE OF TWO CLOSE ANALOGUES**

**BROAD-SPECTRUM ANTIPARASITIC AGENT (ANTHELMINTIC) NEGLECTED TROPICAL DISEASES**

**TAKEN ANNUALLY FREE OF CHARGE BY 250 MILLION PEOPLE**



[*Streptomyces avermitilis*]






« RIVER BLINDNESS » (ONCHOCERCIASIS, *ONCHOCERCA VOLVULUS*)




« ELEPHANTIASIS » (LYMPHATIC FILARIASIS, *WUCHERERIA BANCROFTI*)


# Fungi and antibiotics




## Currently used natural penicillins



benzylpenicillin = penicillin G  
historically *aka* "american penicillin"



phenoxymethylpenicillin = penicilline V





# Natural products and pharmaceutical industry

✓ 1940-1960 : High scale production of penicillin during the World War II (golden age era)

Antibiotics : Tetracyclins, aminosides, glycopeptides


✓ 1960-1990 : Lipid-lowering medications (lovastatines), anticancer drugs: vinblastine (1965) , taxol (1967), antimalarials (quinine, artemisinin), immunosuppressants

**Life expectancy in much of the world lengthened from about 40 years early in the 20<sup>th</sup> century to more than 77 years today.**

# Natural products and pharmaceutical industry

1990 - 2000 :

- ✓ Development of High-throughput Screening (HTS): chemical libraries
- ✓ Emergence of combinatorial chemistry



# Natural products and pharmaceutical industry

1990-2000:


Industry reluctance to pursue NP-based drug discovery program:

- ✓ Elimination of their NP research programs







# What could be the reasons of this reluctance?



# Chemical process for natural product discovery



# Generic scheme for bioassay-guided fractionation



- ✓ Bioguided fractionation using **cell-based assays** (assessment of molecular interactions within the context of a living cellular environment)
- ✓ Bioguided fractionation using **biochemical-assays** has the advantage of providing target-specific information.



# What could be the reasons of this reluctance ?

## ✓ **Incompatibility with the pharmaceutical environment**

Firms involved in drug discovery must hit the target not only accurately, but very quickly and very profitably. However, for reasons outlined below, natural product sources are currently not very amenable to rapid high-throughput screening (HTS).

## ✓ **Difficulties in discovering natural product drug candidates**

In contrast to synthetic libraries, hits from natural sources are likely to have complex structures with numerous oxygen-containing substituents and an abundance of centers of stereochemistry rendering their optimization very difficult.

## **Dealing with mixtures !**

the initial extract of the natural material usually consists of a complex mixture after fractionation. It may contain only very small quantities of a bioactive substance, often as a mixture with structurally related molecules. The initial concentration of an interesting compound may be too low to be effectively detected by HTS, or the assay may be obscured by poor solubility or by fluorescent or colored contaminants. The key compound may be unstable in the mixture. A further complication can be synergistic (or antagonistic) activity of two constituents that may then diminish or disappear upon separation.

# What could be the reasons of this reluctance ?



## ✓ **Problems of supply and manufacture**

Intellectual property concerns of local governments and the Rio and Nagoya Conventions on Biodiversity.

Seasonal or environmental variations in the composition of living organisms.

**A prevailing sentiment** in many pharmaceutical organizations is that screening of natural product sources is a difficult effort with a high probability of duplication; that is, the result may be a known compound that cannot be patented.

**However**, fewer than 1% of microorganism species are easily cultured, and perhaps fewer than 15% of higher plant species have been examined for bioactivity. Certain insects and other animals have been targeted for specific bioactivities, such as toxins, but are not generally subjected to HTS efforts. Clearly the biological resource is there, but access and examination are problematic, especially if there is pressure for a short time frame for discovery of new leads.


# Natural product discovery approaches

- ✓ Development of advanced **analytical techniques** (*hyphenated methods* : LC-MS-NMR) and **dereplication** (avoiding the isolation of already known NPs)
- ✓ Development of natural product databases (DNP, MarineLit)



100 000 extracts



1. Rapid, automated C<sub>18</sub> HPLC separation
2. Bioassay on collected fractions
3. MS/nitrogen/NMR analysis of active fractions



Selecting for uniqueness and lead-like properties  
(Potency, log  $P < 5$ , MW < 550)







# « non-cultivable » bacteria

99

percent

of all microbial species on Earth have yet to  
be discovered







# Advanced culture techniques: In-situ cultivation




I-chip




# Renewing interests

- ✓ **Targeted therapies:** Reusing old toxic natural products as Antibody-drug conjugates (ADC) directed toward identified targets (tumor-specific antigens abundant in tumor tissue but minimally expressed in normal tissues)



# Renewing interest




*MAYTENUS SERRATA*

- ✓ Isolated in 1960 from *Maytenus serrata*
- ✓ Failure of clinical trials in 1980.




# Renewing interest




- ✓ Breast cancer (*Her2* positive)
- ✓ Approved in Europe in 2013.

# Renewing interest



- ✓ Isolated in 1980 from *Dolabella auricularia* (very low amounts)
- ✓ Sub-nanomolar cytotoxicity

# Renewing interest



## *BRENTUXIMAB VEDOTIN*

- ✓ Hodgkin lymphoma CD30 positive
- ✓ Marketed in 2013.



# Natural products-based approved drugs

1981-2020 : all new approved drugs (FDA, 1881)

« synthetic drug with NP pharmacophore » **25.7 %**

« vaccine » **7.5 %**

« biologics » **18.4 %**

S\*, 65, 3.2

N, 71, 3.8

NB, 14, 0.8

**49 % inspired from NPs**

« NPs and semisynthetic » **23.5 %**

S/NM, 217, 11.5

ND, 356, 18.9

S, 463, 24.6

**29 %**

« synthetic »

# Conclusions




# Conclusions


- ✓ NPs remain a promising pool for the discovery of scaffold with structural diversity and various bioactivities that can be directly developed or used as starting points for optimization into novel drugs.
- ✓ The last 40 years have seen a remarkable exploration of the marine environment.
- ✓ The explosion of numerous « omic » approaches- genomics, proteomics, metabolomics and transcriptomics-has empowered researchers with the ability to address fundamental questions
- ✓ Advances in synthetic biology in order to address supply problems
- ✓ The futur of NP research lies in multidisciplinary project between academia and industry in small biotechnology companies




## Digital DNA collection



## Heterologous expression



## Molecules in vials



Annu. Rev. Biochem. 2024. 93:20.1–20.35

A lush green forest with sunlight filtering through the trees. The scene is filled with vibrant green foliage and tall, slender tree trunks. The ground is covered in moss and fallen leaves, with a small stream or path visible in the lower right. The overall atmosphere is serene and natural.

Thank you for your  
attention



# Chemical space

- *A COLLECTION OF CHEMICAL COMPOUNDS THAT CAN BE CHARACTERIZED BY A WIDE RANGE OF MOLECULAR DESCRIPTORS (50 DESCRIPTORS: MW, POLARITY, C,N,O NUMBER, ...)*
- *CHEMICAL SPACE IS DEFINED AS THE TOTAL DESCRIPTOR SPACE THAT ENCOMPASSES ALL THE SMALL CARBON-BASED MOLECULES THAT COULD IN PRINCIPLE BE CREATED.*


## *- DRUG CHEMICAL SPACE:*

*MW < 500, < 30 atoms non H, with only C, H, O, N, P, S, F, Cl, Br, stable at room temperature, with water and oxygene*

*=  $10^{63}$  MOLECULES !!*



# Natural products and chemical space



*Efficient chemical space coverage*

